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Abstract The present study showed that sphingosine 1-phos-
phate (SPP) induced rapid stimulation of phospholipase D
(PLD) in skeletal muscle C2C12 cells. The effect was receptor-
mediated since it was fully inhibited by pertussis toxin. All known
SPP-specific receptors, Edg-1, Edg-3 and AGR16/H218, re-
sulted to be expressed in C2C12 myoblasts, although at a
different extent. SPP-induced PLD activation did not involve
membrane translocation of PLD1 or PLD2 and appeared to be
fully dependent on protein kinase C (PKC) catalytic activity.
SPP increased membrane association of PKCK, PKCN and
PKCV, however, only PKCK and PKCN played a role in PLD
activation since low concentrations of GF109203X and rottlerin,
a selective inhibitor of PKCN, prevented PLD stimulation.
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Key words: Phospholipase D; Sphingosine 1-phosphate;
Protein kinase C; C2C12 myoblast; Edg receptor
1. Introduction
Phospholipase D (PLD), a well-known enzyme responsible
for the hydrolysis of phosphatidylcholine (PtdCho) and/or
phosphatidylethanolamine to phosphatidic acid (PtdOH)
and, respectively, choline or ethanolamine, is an important
e¡ector in cell signaling [1].
Two mammalian PLDs, PLD1 and PLD2, have recently
been cloned, both widely expressed in many cell types and
tissues [1]. PLD2, which has been less characterized than
PLD1, appears to be constitutively active and under the con-
trol of physiological regulators not di¡erent from those of
PLD1 [2,3]. Agonist-stimulated PLD activity absolutely re-
quires phosphatidylinositol 4,5-bisphosphate as cofactor and
appears to be highly regulated by a complex group of pro-
teins, including protein kinase C (PKC), monomeric G pro-
teins and protein-tyrosine kinases [1]. However, the exact or-
der of events leading from receptor occupancy by ligand to
PLD activation and their relative importance are not com-
pletely de¢ned. Many studies generally support the involve-
ment of PKC in the action of many G protein-linked agonists
and growth factors on PLD in vivo, although negative or
partial e¡ects have been observed in some studies [1]. Among
the known isoenzymes of PKC, the calcium-dependent forms
are reported to play a major role in PLD regulation [1].
In skeletal muscle cells, several agonists including vasopres-
sin, bradykinin (BK), thrombin and calcitriol can activate
PLD [4^6], indicating that the enzyme is a key component
of the membrane signaling machinery in this cell type.
Sphingosine 1-phosphate (SPP) is a member of a new class
of lipid messengers important for the regulation of growth-
related processes and cellular e¡ector functions which are de-
pendent on cytoskeletal responses [7]. SPP speci¢cally binds to
prototypical members of the orphan endothelial di¡erentia-
tion gene family Edg that includes until now Edg-1, Edg-3
and AGR16/H218 proteins. All known members of the Edg
receptor family have been demonstrated to be coupled to het-
erotrimeric G proteins and to be responsible for speci¢c
downstream e¡ects, including calcium mobilization, activation
or inhibition of adenylate cyclase and mitogen-activated pro-
tein kinase activation [7].
SPP has been shown to stimulate PLD activity in a number
of di¡erent cell types [8^10]. However, the exact signaling
pathway involved has not been clari¢ed. Moreover, in a recent
report, the e¡ect of SPP on PLD activation was found to be
independent from Edg-1 receptor and suggested to be medi-
ated by SPP internalization [10].
Here, we present evidence that SPP rapidly and transiently
activates PLD in C2C12 mouse skeletal muscle cells. Both
PLD isoforms appeared to be expressed in C2C12 myoblasts.
SPP failed to increase membrane association of PLD1 or
PLD2, indicating that SPP-induced enzyme activation did
not require translocation of PLD from cytosol to the mem-
brane. The activation of PLD is triggered by a receptor-medi-
ated pertussis toxin (PTx)-sensitive G protein pathway and
involves, besides PKCK, also the calcium-independent isoform
PKCN.
2. Materials and methods
2.1. Materials
[3H]glycerol (30^60 Ci/mmol) was purchased from Du Pont NEN
(Boston, MA, USA), standard lipids were from Avanti Polar Lipids
(Alabaster, AL, USA), solvents and silica gel 60 plates for thin-layer
chromatography (TLC) from Merck (Darmstadt, Germany), BK,
RedTaq polymerase, TriReagent and other chemicals were from Sig-
ma (St. Louis, MO, USA). Sphingosine 1-phosphate was from Cal-
biochem (San Diego, CA, USA), pertussis toxin was from List Bio-
logical Labs (Campbell, CA, USA). Mouse monoclonal antibodies
against the speci¢c isoforms of PKC were from Transduction Labo-
ratories (Lexington, KY, USA). PLD1 and PLD2 anti-peptide anti-
bodies were a generous gift of Dr S. Bourgoin (Ste-Foy, Que., Can-
ada) and were generated as described ([11], Houle, M.G. and
Bourgoin, S., personal communication). Superscript II Reverse tran-
scriptase was from Life Technologies (Eggenstein, Germany). Second-
ary antibodies (goat anti-mouse or anti-rabbit immunoglobulin G1
conjugated) were from Santa Cruz (Santa Cruz, CA, USA).
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2.2. Muscle cell culture
Mouse skeletal C2C12 myoblasts [12] were obtained from ATCC
(Manassas, VA, USA) and maintained as previously described [5].
2.3. Measurement of PLD activity and [3H]PtdOH levels
PLD activity was determined by measuring [3H]phosphatidyl-
ethanol ([3H]PtdEtOH) produced via PLD-catalyzed transphosphati-
dylation in serum-starved cells labelled for 24 h with 5 WCi/ml
[3H]glycerol and stimulated in the presence of 2% ethanol. Cells
were collected by scraping, lipids were extracted and [3H]PtdEtOH
was measured after TLC separation essentially as described by Meacci
et al. [13]. [3H]PtdOH levels were measured as described by Vasta et
al. [5].
2.4. Expression of Edg receptors in C2C12 cells by reverse transcription
(RT)-PCR
Total cellular RNA used to prepare cDNA was isolated using
TriReagent. The RT reaction was performed at 42‡C for 1 h in
20 Wl of 50 mM KCl, 2.5 mM Tris-HCl (pH 8.4), 2 mM dNTPs
(0.5 mM each), 200 ng of random hexamers as primers, 200 ng oli-
go(dT), 10 mM DTT, 5 Wg of total cellular RNA using 200 U of
Superscript II RT. To terminate the reaction, samples were incubated
at 70‡C for 15 min. The resulting cDNA was used directly for PCR.
Mouse Edg-1-speci¢c PCR primers (CCTATCATGGGCTGGA-
ACTGCATC and CCCCAGAAGGACGATGGGGACAACCCA),
mouse Edg-3-speci¢c PCR primers (GCAACCACGCATGCGCAG-
GGCCACCAGGG and GGAAAAACAATAAATTTCACAACCG-
C), AGR16/H218-speci¢c PCR primers (GGCAGCGACAAGA-
GCTGCCGCATG and CTGGAGGGCAACACGGTGGTCTGA)
were synthesized by Pharmacia Biotech (Uppsala, Sweden). PCR
was carried out in 50 Wl of 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2, 0.8 mM dNTPs (200 WM of each), 0.5 WM of each
primer using 2 Wl of RedTaq DNA polymerase. cDNA (50 ng) was
added as PCR template. 30 Cycles of ampli¢cation were carried out as
follows: at 92‡C for 40 s, at 57‡C for 40 s and at 72‡C for 90 s. PCR
products (8 Wl) were analyzed by electrophoresis in a 1.8% agarose gel.
2.5. Cellular fractionation
Serum-starved C2C12 cells were treated or not with 1 WM SPP for
30 s. The medium was removed and the cells washed twice with ice-
cold PBS, scraped and collected by centrifugation at 1000Ug. The cell
pellet was resuspended in bu¡er A (20 mM HEPES, pH 7.4, 2 mM
EGTA, 1 mM EDTA, 250 mM sucrose, 5 mM NaN3) containing
protease inhibitors (1 mM AEBSF, 0.3 WM aprotinin, 10 Wg/ml leu-
peptin and 10 Wg/ml pepstatin) and homogenized in a Dounce (60
strokes).
Lysates were centrifuged for 7 min at 500Ug to separate nuclei. To
prepare cytosolic and total particulate fractions, the supernatant was
centrifuged at 200 000Ug for 1 h. The pellet was resuspended in the
same bu¡er, containing 1% Triton X-100, incubated in ice for 30 min
and successively centrifuged at 200 000Ug for 50 min to prepare Tri-
ton X-100-soluble and -insoluble membrane fractions.
2.6. Western blot analysis
Proteins (30 Wg) from cellular fractions of unstimulated and ago-
nist-stimulated myoblasts were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Immunoblotting
was performed as described [11].
2.7. Presentation of data and statistical analysis
The data were analyzed by StudentPs t-test and P6 0.05 was con-
sidered signi¢cant. All data are presented as the mean þ S.E.M. of at
least three separated experiments performed in duplicate. In immuno-
blot experiments, a blot representative of at least three similar experi-
ments is presented.
3. Results
3.1. SPP induces PLD activation in myoblasts
Incubation of intact [3H]glycerol-labelled C2C12 myoblasts
with SPP led to a signi¢cant increase in PLD activity. PLD
activation was very rapid reaching a maximum at 1 min and
was still detectable after 5 min (Fig. 1A). In the presence of
2% ethanol, SPP failed to increase [3H]PtdOH signi¢cantly
(2.0 þ 0.15 and 5.5 þ 0.7% PtdOH/PtdCho in the absence of
ethanol in unstimulated and SPP-treated cells, respectively
(P6 0.05, n = 3); 2.05 þ 0.16 and 2.42 þ 0.25% PtdOH/PtdCho
in the presence of ethanol in unstimulated and SPP-treated
cells, respectively (n = 3)), indicating that stimulation of PLD
played a major role in the transient rise of PtdOH levels
induced by SPP. PLD activation by SPP was dose-dependent
with a half-maximal e¡ect with approximately 50 nM SPP
(Fig. 1B).
3.2. PLD activation by SPP is sensitive to PTx
SPP-induced PLD activation was totally prevented in cells
previously treated with 200 ng/ml PTx for 16 h, indicating
that the bioactive lipid acts through a Gi or Go protein-
coupled receptor (Table 1). In parallel experiments, BK, a
pro-in£ammatory peptide able to stimulate PLD activity in
these cells [5], was not a¡ected by PTx, in agreement with a
signaling pathway triggered through Gq-coupled receptors.
3.3. Expression of Edg receptors in C2C12 myoblasts
The expression of Edg-1, Edg-3 and AGR16/H218 was an-
alyzed in C2C12 myoblasts by RT-PCR using total cellular
RNA. Fig. 2 shows the agarose gel in which RT-PCR prod-
ucts were electrophoretically separated. cDNAs corresponding
Fig. 1. Time-course and dose-dependence of the e¡ect of SPP on PLD activation. [3H]glycerol-labelled C2C12 cells were stimulated with 1 WM
SPP in the presence or absence of 2% ethanol for the indicated time (A) or with di¡erent concentrations of SPP for 10 min (B). Lipids were
then extracted and [3H]PtdEtOH, [3H]PtdOH and [3H]PtdCho were determined as described in Section 2.
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to the expected length of Edg-1 (563 bp), Edg-3 (225 bp) and
AGR16/H218 (621 bp) were detected. No PCR product was
visible in control experiments in the absence of template DNA
(data not shown).
3.4. Expression of PLD isoforms and the e¡ect of SPP
treatment on the protein subcellular distribution
PLD1-speci¢c antibodies recognized a protein band of ap-
proximately 120 kDa and two others of 85 and 50 kDa (Fig.
3). The two higher bands were not recognized by peptide-
neutralized PLD1 antibodies (data not shown). The 50 kDa
band might be a contaminant protein.
Immunoblot analysis of PLD2 showed a single band at
approximately 90 kDa in cytosol and two bands around 100
and 90 kDa in a Triton X-100-insoluble membrane (Fig. 3).
Peptide-neutralized antibodies did not detect any band (data
not shown).
PLD1 and PLD2 resulted to be di¡erently localized: both
isoforms were present in soluble and particulate fractions,
however, PLD1 was mainly associated with the Triton-soluble
membrane fraction, while PLD2 was mostly detected in the
Triton-insoluble membrane fraction.
Treatment with 1 WM SPP for 30 s did not alter the intra-
cellular distribution of both PLD isoforms (Fig. 3).
3.5. SPP-induced PLD activation is dependent on PKC
activation
Immunoblot analysis showed that the following PKCs
could be dominantly detected in unstimulated C2C12 myo-
blasts : PKCK, PKCN, PKCV and PKCW. PKCL, O and j
were not detected (data not shown). Since it is known that
the PKC content in a particulate fraction can re£ect PKC
activity, the e¡ect of SPP on the pool of PKC associated
with the membrane was examined to investigate its role in
PLD activation. Treatment with 1 WM SPP for 30 s induced
a rapid translocation of PKCK to the Triton X-100-soluble
membrane fraction (Fig. 4). The activation was indeed tran-
sient, at 10 min of stimulation, membrane-associated PKCK
appeared signi¢cantly decreased (data not shown). Moreover,
SPP could also induce membrane translocation of the calci-
um-independent forms, PKCN and PKCV, but did not a¡ect
the pool of PKCW (Fig. 4). To examine the role of PKC
catalytic activity in the SPP action on PLD, GF109203X,
which has been reported to be a stronger inhibitor of classical
PKC than novel PKC [14], and rottlerin, a selective inhibitor
of PKCN [15], were used. Treatment of C2C12 myoblasts with
GF109203X diminished SPP-induced PLD activation approx-
imately by 50% at 5 WM and blocked the stimulation at 10 WM
(Fig. 5A). Similar results were achieved with Ro 31-8220 and
Table 1









3 3 3 0.42 þ 0.05
3 + 3 0.80 þ 0.06*
3 3 + 0.97 þ 0.10*
+ 3 3 0.52 þ 0.06
+ + 3 0.53 þ 0.03
+ 3 + 1.18 þ 0.11*
Con£uent myoblasts were labelled with [3H]glycerol for 16 h in the
presence or absence of 200 ng/ml of PTx before stimulation with
1 WM SPP or 1 WM BK for 10 min in the presence of 2% ethanol.
[3H]PtdEtOH formation was quanti¢ed as described in Section 2.
*Statistical signi¢cant (P6 0.05).
Fig. 2. Expression of Edg receptor isoforms in C2C12 myoblasts as
assessed by RT-PCR. An ethidium bromide-stained 1.8% agarose
gel is shown after separation of RT-PCR products. The experiment
was repeated three times with similar results. Lane 1 shows DNA
molecular markers (GeneRuler DNA Ladder Mix).
Fig. 3. Intracellular distribution of PLD1 and PLD2. Proteins (30
Wg) from the cytosol (Cyt), 1% Triton X-100-soluble (Memb sol),
1% Triton X-100-insoluble membrane fraction (Memb insol) or nu-
clei (N) prepared from myoblasts treated or not with 1 WM SPP for
30 s were separated by SDS-PAGE (8%) and Western analysis per-
formed as described in Section 2. PLD1 and PLD2 were detected
using polyclonal anti-rabbit antibodies kindly provided by Dr S.
Bourgoin.
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down-regulation of PKC by prolonged treatment (20 h) with
800 nM PMA (data not shown). Interestingly, the stimulation
of PLD activity by SPP was also inhibited in a dose-depend-
ent manner by rottlerin (Fig. 5B), indicating a crucial role for
PKCN in the SPP-induced PLD activation.
4. Discussion
We have demonstrated here that SPP stimulates PLD ac-
tivity, which accounts for the SPP-induced increase of PtdOH
levels, in a receptor-mediated manner. The ¢nding that SPP-
induced activation of PLD was abolished by treatment with
PTx clearly indicates that in C2C12 muscle cells, SPP acts as
ligand for one or more Gi-coupled receptor(s) and provides
evidence for a fully Gi-dependent signaling pathway directly
involved in PLD regulation. In agreement, the concentrations
of SPP capable to increase PLD activity were in the same
range as the Kd values reported for the SPP receptors [7].
Analysis by RT-PCR showed that all known SPP-speci¢c
Edg receptors were expressed at the mRNA level, although
at a di¡erent extent. This is the ¢rst evidence for mRNA
expression of all described Edg receptors in skeletal muscle
cells. Because Edg-1 and AGR16/H218 can be coupled to Gi
proteins [16,17] and were both expressed in myoblasts, it is
not possible to attribute the observed SPP-induced signaling
pathway to a distinct receptor.
Determination of PLD1 and PLD2 expression in various
tissues indicates that skeletal muscle has relatively low levels
of mRNA for both isoforms [18]. Here, we reported for the
¢rst time that PLD1 and PLD2 proteins are both expressed in
C2C12 myoblasts and are di¡erently distributed in Triton X-
100-soluble and -insoluble membrane fractions, suggesting
that the two isoforms are associated to di¡erent membrane
microdomains. Translocation to the cytoskeleton of PLD1 has
been reported after treatment with opsonized zymosan in
U937 cells [19] and also PLD2 redistribution upon serum
stimulation has been observed [2]. However, in our cell sys-
tem, SPP failed to increase membrane association either of
PLD1 or PLD2, excluding that enzyme translocation from
cytosol to the membrane is a step in agonist-induced PLD
activation. This is in agreement with a previous observation
in PC-3, human prostate cancer cells [20].
Studies in L6 myoblasts demonstrated the presence of sev-
eral PKC isoforms [21], but, so far, a full characterization of
PKC isoforms expressed in mouse skeletal muscle C2C12 cells
has not been reported. Here, evidence is provided that PKCK,
PKCN, PKCV and PKCW are dominantly detected in C2C12
myoblasts and that SPP can translocate PKCK, PKCN and
PKCV to the membrane fraction.
Regulation of PLD activities by PKC is complex and phos-
phorylation-dependent and -independent mechanisms for
PKC-dependent PLD activation have been reported [1]. Re-
markably, in the present study, SPP-induced PLD activation
was totally prevented by inhibition of PKC. Since the PKC
inhibitors used, GF109203X and rottlerin, compete for bind-
ing of ATP to PKCs, our results imply that phosphorylation
is required for PLD stimulation, as previously proposed
[22,23]. However, the present literature can not lead to ex-
clude that phosphorylation-dependent and -independent
mechanisms concur to regulate PLD activity.
An interesting ¢nding is that PKCN catalytic activity is in-
volved in SPP stimulation of PLD as demonstrated by the
e⁄cacy of rottlerin, reported to be speci¢c for PKCN [15].
So far, a role for PKCN as PLD activator has been reported
in in vitro experiments [24]. The involvement of PKCK in the
regulation of PLD activity has been widely investigated in
vivo and in vitro [1]. Here, evidence is provided for a role
of PKCK in the SPP signaling pathway in C2C12 cells.
PKCK is likely involved in the agonist-induced stimulation
of PLD in view of the observed reduction of enzyme activa-
Fig. 4. E¡ect of SPP on PKC isoform membrane association. Se-
rum-starved myoblasts were incubated in the absence or in the pres-
ence of 1 WM SPP for 30 s. Proteins (30 Wg) from the 1% Triton
X-100-soluble membrane fraction of control (C) or SPP-stimulated
cells (SPP) were separated by SDS-PAGE (8%) and Western analy-
sis performed as described in Section 2.
Fig. 5. E¡ect of PKC inhibitors on SPP-induced PLD activation.
Con£uent myoblasts were labelled with [3H]glycerol and incubated
without or with the indicated concentrations of GF109203X (A) or
rottlerin (B) for 30 min prior to incubation with vehicle (0.05%
DMSO) or 1 WM SPP for 10 min in the presence of 2% ethanol (b
control cells, F SPP-treated cells). [3H]PtdEtOH formation was
quanti¢ed as described in Section 2. *Statistical signi¢cance of PKC
inhibition of SPP-induced PLD activation (P6 0.05).
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tion at concentrations of GF109203X which are not e¡ective
on calcium-independent PKC [14].
Although SPP induced also PKCV translocation, it ap-
peared not to be required for PLD activation, as suggested
by the observed GF109203X-independent membrane associa-
tion of this isoform at a high concentration of inhibitor (data
not shown).
The here reported results are consistent with a model in
which SPP-dependent PLD activation is fully mediated by
PTx-sensitive G protein-coupled receptor(s) and mainly re-
quires PKCK and PKCN activation. Further studies are re-
quired to clarify in more details the SPP receptor-mediated
events upstream of PKC activation.
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